In Vitro Diagnostics (IVD) include reagents, instruments, and systems intended for use in the diagnosis of disease or other conditions, including the determination of the state of health, in order to treat or prevent disease. The reagents, instruments and systems are intended for use in the collection, preparation, and examination of specimens taken from the human body. The categories tracked under this market are Cardiac Disease, Hematological Disorders, Hormonal Disorders, Metabolic Disorder, Infectious Disease, IVD Analyzers and Reagents, Oncology and Reproductive Health Diagnostics. Cytomegalovirus (CMV) tests are used for the detection of CMV, which can cause serious illness in immunocompromised patients, and infants, with up to 1 in 3 children being infected and over half of adults by the age of 40 in the United States. GlobalData uses proprietary data and analytics to provide a comprehensive report on the cytomegalovirus (cmv) tests devices market, including market shares of different players within Italy. Buy the latest report here.

Smarter leaders trust GlobalData

Report-cover

Data Insights Italy Cytomegalovirus (CMV) Tests Market Share

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

In 2022, GlobalData’s Market Model methodology determined that the leading player in the cytomegalovirus (cmv) tests market in Italy was Abbott Laboratories followed by DiaSorin, F. Hoffmann-La Roche, Qiagen, bioMerieux, Bio-Rad Laboratories, Quidelortho, Siemens, Danaher, Erba Diagnostics Mannheim, Merck, Luminex, Altona Diagnostic, Trinity Biotech, Immucor, StatLab Medical (SLMP) and MBL International.

CMV infections are most prevalent in pregnant women, immunocompromised patients, and infants. CMV testing is usually performed with the help of Enzyme Immuno Assay (EIA) Tests, Nucleic Acid Amplification Tests (NAATs), and other tests. The tests carried out in laboratories are considered. The CMV Test market includes the sub-segments Cytomegalovirus (CMV) Enzyme Immuno Assay/Enzyme Linked Immunosorbent Assay (EIA/ELISA) Tests, Cytomegalovirus (CMV) Nucleic Acid Amplification Tests (NAATs), and Other Cytomegalovirus (CMV) Tests.

Following the widespread disruption resulting from the COVID-19 pandemic to the broader medical devices market during 2020 and 2021, the value of the cytomegalovirus (cmv) tests devices market within Italy was expected to be over $1m in 2022.

For the latest complete market share analysis of cytomegalovirus (cmv) tests device market in Italy, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article. 

The medical devices pipeline data used in this article were obtained from the Medical Pipeline Products Database of GlobalData’s Medical Intelligence Center. Pipeline Products database is a comprehensive source of information on medical devices, it covers 39K products which are in development stage and intended for diagnosis, treatment, and management of diseases/conditions/symptoms directly or indirectly. The pipeline products included in the database are sourced from reliable and authenticated sources, such as company websites, SEC filings, conference presentations, analyst presentations, news releases, clinical trial registries, and grants. The information is collected by following systematic research techniques and proprietary methodology.